Therapeutic activity of glycoengineered anti-GM2 antibodies against malignant pleural mesothelioma.
Bottom Line: BIW-8962 showed a significant antibody-dependent cellular cytotoxicity activity against the GM2-expressing MPM cell line MSTO-211H, the effect of which depended on the antibody concentration and effector/target ratio.Additionally, the GM2 expression was confirmed in the MPM clinical specimens.These data suggest that anti-GM2 antibodies may become a therapeutic option for MPM patients.
Affiliation: Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.Show MeSH
Related in: MedlinePlus
Mentions: The in vitro ADCC activity of BIW-8962 against the MPM cell line was determined using MNCs obtained from four healthy volunteers as effector cells and MSTO-211H, as target cells, which highly express GM2. Consequently, BIW-8962 showed significant ADCC activity at antibody concentrations of 1 and 10 μg/mL (Fig.2), the efficacy of which increased in correlation with the E/T ratio (25, 50, and 100). The potent ADCC activity of BIW-8962 was consistently observed in MNCs obtained from the four donors.
Affiliation: Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.